The time-series behavior of systemic inflammation-immune status in predicting survival of locally advanced non-small cell lung cancer treated with chemoradiotherapy
Background: Systematic inflammation is believed to play a crucial role in tumorigenesis and metastasis. This study aims at evaluating the prognostic value of time-series behavior of systematic inflammation-immune status before and after definitive chemoradiotherapy (dCRT) in patients with locally ad...
| Main Authors: | , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2022-03-01
|
| Series: | Journal of the National Cancer Center |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2667005421000508 |
| _version_ | 1818243826018418688 |
|---|---|
| author | Tao Zhang Jianyang Wang Daquan Wang Kunpeng Xu Linfang Wu Xin Wang Wenqing Wang Lei Deng Jun Liang Jima Lv Zhouguang Hui Zongmei Zhou Qinfu Feng Zefen Xiao Dongfu Chen Jie Wang Luhua Wang Nan Bi |
| author_facet | Tao Zhang Jianyang Wang Daquan Wang Kunpeng Xu Linfang Wu Xin Wang Wenqing Wang Lei Deng Jun Liang Jima Lv Zhouguang Hui Zongmei Zhou Qinfu Feng Zefen Xiao Dongfu Chen Jie Wang Luhua Wang Nan Bi |
| author_sort | Tao Zhang |
| collection | DOAJ |
| description | Background: Systematic inflammation is believed to play a crucial role in tumorigenesis and metastasis. This study aims at evaluating the prognostic value of time-series behavior of systematic inflammation-immune status before and after definitive chemoradiotherapy (dCRT) in patients with locally advanced non-small cell lung cancer (LA-NSCLC). Methods: The relationship between systematic inflammation-immune score (SIS, defined as pretreatment peripheral platelet count × neutrophil count/lymphocyte count) and the prognosis was tested in a retrospective study of 386 consecutive LA-NSCLC patients (Group A) with pretreatment SIS and 161 patients (Group B) with SIS before and one month after the dCRT. Results: SIS of 1400 × 109 was found to be an optimal cutoff point to stratify the patients into high (>1400 × 109) and low (≤1400 × 109) SIS groups. Univariate and multivariate analyses revealed that the SIS, whether before or after dCRT, was an independent predictor for overall survival (OS), progress-free survival (PFS), and distant metastasis-free survival (DMFS). High SIS (>1400 × 109) was shown to predict poor 3-year OS (P=0.006, hazard ratio [HR]=2.427), PFS (P=0.001, HR=2.442) and DMFS (P=0.015, HR=2.119). However, SIS was not related to local regional recurrence-free survival in either Group A (P=0.346) or Group B (P=0.486). Further, the area under the receiver operating characteristic curve of the SIS for OS was higher than the neutrophil count/lymphocyte count ratio, platelet count/lymphocyte count ratio, and other conventional clinic-pathological indices. Conclusions: The SIS is a stable and more sensitive survival predictor than other inflammation-based factors and conventional clinical indices, which may aid in more accurately stratifying patients for risk assessment and treatment decisions. |
| first_indexed | 2024-12-12T14:07:17Z |
| format | Article |
| id | doaj.art-9d05ff352b9c46408a90029b762806f8 |
| institution | Directory Open Access Journal |
| issn | 2667-0054 |
| language | English |
| last_indexed | 2024-12-12T14:07:17Z |
| publishDate | 2022-03-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Journal of the National Cancer Center |
| spelling | doaj.art-9d05ff352b9c46408a90029b762806f82022-12-22T00:22:10ZengElsevierJournal of the National Cancer Center2667-00542022-03-01213340The time-series behavior of systemic inflammation-immune status in predicting survival of locally advanced non-small cell lung cancer treated with chemoradiotherapyTao Zhang0Jianyang Wang1Daquan Wang2Kunpeng Xu3Linfang Wu4Xin Wang5Wenqing Wang6Lei Deng7Jun Liang8Jima Lv9Zhouguang Hui10Zongmei Zhou11Qinfu Feng12Zefen Xiao13Dongfu Chen14Jie Wang15Luhua Wang16Nan Bi17Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, ChinaDepartment of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, ChinaDepartment of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, ChinaDepartment of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, ChinaDepartment of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, ChinaDepartment of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, ChinaDepartment of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, ChinaDepartment of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, ChinaDepartment of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, ChinaDepartment of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, ChinaDepartment of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, ChinaDepartment of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, ChinaDepartment of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, ChinaDepartment of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, ChinaDepartment of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, ChinaDepartment of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, ChinaDepartment of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China; Corresponding authors.Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China; Corresponding authors.Background: Systematic inflammation is believed to play a crucial role in tumorigenesis and metastasis. This study aims at evaluating the prognostic value of time-series behavior of systematic inflammation-immune status before and after definitive chemoradiotherapy (dCRT) in patients with locally advanced non-small cell lung cancer (LA-NSCLC). Methods: The relationship between systematic inflammation-immune score (SIS, defined as pretreatment peripheral platelet count × neutrophil count/lymphocyte count) and the prognosis was tested in a retrospective study of 386 consecutive LA-NSCLC patients (Group A) with pretreatment SIS and 161 patients (Group B) with SIS before and one month after the dCRT. Results: SIS of 1400 × 109 was found to be an optimal cutoff point to stratify the patients into high (>1400 × 109) and low (≤1400 × 109) SIS groups. Univariate and multivariate analyses revealed that the SIS, whether before or after dCRT, was an independent predictor for overall survival (OS), progress-free survival (PFS), and distant metastasis-free survival (DMFS). High SIS (>1400 × 109) was shown to predict poor 3-year OS (P=0.006, hazard ratio [HR]=2.427), PFS (P=0.001, HR=2.442) and DMFS (P=0.015, HR=2.119). However, SIS was not related to local regional recurrence-free survival in either Group A (P=0.346) or Group B (P=0.486). Further, the area under the receiver operating characteristic curve of the SIS for OS was higher than the neutrophil count/lymphocyte count ratio, platelet count/lymphocyte count ratio, and other conventional clinic-pathological indices. Conclusions: The SIS is a stable and more sensitive survival predictor than other inflammation-based factors and conventional clinical indices, which may aid in more accurately stratifying patients for risk assessment and treatment decisions.http://www.sciencedirect.com/science/article/pii/S2667005421000508Systemic immune-inflammation statusLocally advancedNon-small cell lung cancerChemoradiotherapyPrognosis |
| spellingShingle | Tao Zhang Jianyang Wang Daquan Wang Kunpeng Xu Linfang Wu Xin Wang Wenqing Wang Lei Deng Jun Liang Jima Lv Zhouguang Hui Zongmei Zhou Qinfu Feng Zefen Xiao Dongfu Chen Jie Wang Luhua Wang Nan Bi The time-series behavior of systemic inflammation-immune status in predicting survival of locally advanced non-small cell lung cancer treated with chemoradiotherapy Journal of the National Cancer Center Systemic immune-inflammation status Locally advanced Non-small cell lung cancer Chemoradiotherapy Prognosis |
| title | The time-series behavior of systemic inflammation-immune status in predicting survival of locally advanced non-small cell lung cancer treated with chemoradiotherapy |
| title_full | The time-series behavior of systemic inflammation-immune status in predicting survival of locally advanced non-small cell lung cancer treated with chemoradiotherapy |
| title_fullStr | The time-series behavior of systemic inflammation-immune status in predicting survival of locally advanced non-small cell lung cancer treated with chemoradiotherapy |
| title_full_unstemmed | The time-series behavior of systemic inflammation-immune status in predicting survival of locally advanced non-small cell lung cancer treated with chemoradiotherapy |
| title_short | The time-series behavior of systemic inflammation-immune status in predicting survival of locally advanced non-small cell lung cancer treated with chemoradiotherapy |
| title_sort | time series behavior of systemic inflammation immune status in predicting survival of locally advanced non small cell lung cancer treated with chemoradiotherapy |
| topic | Systemic immune-inflammation status Locally advanced Non-small cell lung cancer Chemoradiotherapy Prognosis |
| url | http://www.sciencedirect.com/science/article/pii/S2667005421000508 |
| work_keys_str_mv | AT taozhang thetimeseriesbehaviorofsystemicinflammationimmunestatusinpredictingsurvivaloflocallyadvancednonsmallcelllungcancertreatedwithchemoradiotherapy AT jianyangwang thetimeseriesbehaviorofsystemicinflammationimmunestatusinpredictingsurvivaloflocallyadvancednonsmallcelllungcancertreatedwithchemoradiotherapy AT daquanwang thetimeseriesbehaviorofsystemicinflammationimmunestatusinpredictingsurvivaloflocallyadvancednonsmallcelllungcancertreatedwithchemoradiotherapy AT kunpengxu thetimeseriesbehaviorofsystemicinflammationimmunestatusinpredictingsurvivaloflocallyadvancednonsmallcelllungcancertreatedwithchemoradiotherapy AT linfangwu thetimeseriesbehaviorofsystemicinflammationimmunestatusinpredictingsurvivaloflocallyadvancednonsmallcelllungcancertreatedwithchemoradiotherapy AT xinwang thetimeseriesbehaviorofsystemicinflammationimmunestatusinpredictingsurvivaloflocallyadvancednonsmallcelllungcancertreatedwithchemoradiotherapy AT wenqingwang thetimeseriesbehaviorofsystemicinflammationimmunestatusinpredictingsurvivaloflocallyadvancednonsmallcelllungcancertreatedwithchemoradiotherapy AT leideng thetimeseriesbehaviorofsystemicinflammationimmunestatusinpredictingsurvivaloflocallyadvancednonsmallcelllungcancertreatedwithchemoradiotherapy AT junliang thetimeseriesbehaviorofsystemicinflammationimmunestatusinpredictingsurvivaloflocallyadvancednonsmallcelllungcancertreatedwithchemoradiotherapy AT jimalv thetimeseriesbehaviorofsystemicinflammationimmunestatusinpredictingsurvivaloflocallyadvancednonsmallcelllungcancertreatedwithchemoradiotherapy AT zhouguanghui thetimeseriesbehaviorofsystemicinflammationimmunestatusinpredictingsurvivaloflocallyadvancednonsmallcelllungcancertreatedwithchemoradiotherapy AT zongmeizhou thetimeseriesbehaviorofsystemicinflammationimmunestatusinpredictingsurvivaloflocallyadvancednonsmallcelllungcancertreatedwithchemoradiotherapy AT qinfufeng thetimeseriesbehaviorofsystemicinflammationimmunestatusinpredictingsurvivaloflocallyadvancednonsmallcelllungcancertreatedwithchemoradiotherapy AT zefenxiao thetimeseriesbehaviorofsystemicinflammationimmunestatusinpredictingsurvivaloflocallyadvancednonsmallcelllungcancertreatedwithchemoradiotherapy AT dongfuchen thetimeseriesbehaviorofsystemicinflammationimmunestatusinpredictingsurvivaloflocallyadvancednonsmallcelllungcancertreatedwithchemoradiotherapy AT jiewang thetimeseriesbehaviorofsystemicinflammationimmunestatusinpredictingsurvivaloflocallyadvancednonsmallcelllungcancertreatedwithchemoradiotherapy AT luhuawang thetimeseriesbehaviorofsystemicinflammationimmunestatusinpredictingsurvivaloflocallyadvancednonsmallcelllungcancertreatedwithchemoradiotherapy AT nanbi thetimeseriesbehaviorofsystemicinflammationimmunestatusinpredictingsurvivaloflocallyadvancednonsmallcelllungcancertreatedwithchemoradiotherapy AT taozhang timeseriesbehaviorofsystemicinflammationimmunestatusinpredictingsurvivaloflocallyadvancednonsmallcelllungcancertreatedwithchemoradiotherapy AT jianyangwang timeseriesbehaviorofsystemicinflammationimmunestatusinpredictingsurvivaloflocallyadvancednonsmallcelllungcancertreatedwithchemoradiotherapy AT daquanwang timeseriesbehaviorofsystemicinflammationimmunestatusinpredictingsurvivaloflocallyadvancednonsmallcelllungcancertreatedwithchemoradiotherapy AT kunpengxu timeseriesbehaviorofsystemicinflammationimmunestatusinpredictingsurvivaloflocallyadvancednonsmallcelllungcancertreatedwithchemoradiotherapy AT linfangwu timeseriesbehaviorofsystemicinflammationimmunestatusinpredictingsurvivaloflocallyadvancednonsmallcelllungcancertreatedwithchemoradiotherapy AT xinwang timeseriesbehaviorofsystemicinflammationimmunestatusinpredictingsurvivaloflocallyadvancednonsmallcelllungcancertreatedwithchemoradiotherapy AT wenqingwang timeseriesbehaviorofsystemicinflammationimmunestatusinpredictingsurvivaloflocallyadvancednonsmallcelllungcancertreatedwithchemoradiotherapy AT leideng timeseriesbehaviorofsystemicinflammationimmunestatusinpredictingsurvivaloflocallyadvancednonsmallcelllungcancertreatedwithchemoradiotherapy AT junliang timeseriesbehaviorofsystemicinflammationimmunestatusinpredictingsurvivaloflocallyadvancednonsmallcelllungcancertreatedwithchemoradiotherapy AT jimalv timeseriesbehaviorofsystemicinflammationimmunestatusinpredictingsurvivaloflocallyadvancednonsmallcelllungcancertreatedwithchemoradiotherapy AT zhouguanghui timeseriesbehaviorofsystemicinflammationimmunestatusinpredictingsurvivaloflocallyadvancednonsmallcelllungcancertreatedwithchemoradiotherapy AT zongmeizhou timeseriesbehaviorofsystemicinflammationimmunestatusinpredictingsurvivaloflocallyadvancednonsmallcelllungcancertreatedwithchemoradiotherapy AT qinfufeng timeseriesbehaviorofsystemicinflammationimmunestatusinpredictingsurvivaloflocallyadvancednonsmallcelllungcancertreatedwithchemoradiotherapy AT zefenxiao timeseriesbehaviorofsystemicinflammationimmunestatusinpredictingsurvivaloflocallyadvancednonsmallcelllungcancertreatedwithchemoradiotherapy AT dongfuchen timeseriesbehaviorofsystemicinflammationimmunestatusinpredictingsurvivaloflocallyadvancednonsmallcelllungcancertreatedwithchemoradiotherapy AT jiewang timeseriesbehaviorofsystemicinflammationimmunestatusinpredictingsurvivaloflocallyadvancednonsmallcelllungcancertreatedwithchemoradiotherapy AT luhuawang timeseriesbehaviorofsystemicinflammationimmunestatusinpredictingsurvivaloflocallyadvancednonsmallcelllungcancertreatedwithchemoradiotherapy AT nanbi timeseriesbehaviorofsystemicinflammationimmunestatusinpredictingsurvivaloflocallyadvancednonsmallcelllungcancertreatedwithchemoradiotherapy |